Landmark approval granted for Phase 1 clinical trial of the novel KMCAR™ T-cell immunotherapy in multiple myeloma (KOALA study). The KMCAR™ T-cell treatment is being developed by Hae-maLogiX, in collaboration with world-leading Centre of Excellence in Cellular Immunotherapy at Peter MacCallum Cancer Centre.
Read article +Findings support the potential of HaemaLogiX’s KappaMab and KMCAR™ cell immunotherapies, the only therapies globally that precisely target KMA-positive myeloma
Read article +In this special investor guide, Tim Boreham showcases 25 pioneering Aussie health and biotech companies passing the clinical test, alongside insights from leading healthcare analysts from Morgans, Cannacord and Platinum Asset Management and Stockhead’s Nadine McGrath.
Read article +HaemaLogiX Ltd, a clinical stage biotech developing novel immunotherapies for patients with blood cancers and B-cell diseases, is pleased to announce the appointment of Dr Chris Baldwin as Chief Executive Officer and Managing Director, effective 5 January 2026.
Read article +